APRI (Aprinoia Therapeutics) FCF Margin %: -26,697.14% (As of Dec. 2023)


What is Aprinoia Therapeutics FCF Margin %?

Aprinoia Therapeutics APRI FCF Margin % is -26,697.14% as of Dec. 2023.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Aprinoia Therapeutics's Free Cash Flow for the six months ended in Dec. 2023 was $-9.34 Mil. Aprinoia Therapeutics's Revenue for the six months ended in Dec. 2023 was $0.04 Mil. Therefore, Aprinoia Therapeutics's FCF Margin % for the quarter that ended in Dec. 2023 was -26,697.14%.

As of today, Aprinoia Therapeutics's current FCF Yield % is 0.00%.

The historical rank and industry rank for Aprinoia Therapeutics's FCF Margin % or its related term are showing as below:


APRI's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -85.21
* Ranked among companies with meaningful FCF Margin % only.

Aprinoia Therapeutics FCF Margin % Related Terms

Aprinoia Therapeutics FCF Margin % Historical Data

* Premium members only.

The historical data trend for Aprinoia Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aprinoia Therapeutics FCF Margin % Chart

Aprinoia Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
FCF Margin %
-4,509.09 -4,886.55 -164.47

Aprinoia Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
FCF Margin % 0.00 -3,622.37 -8,653.54 -61.68 -26,697.14

APRI vs : FCF Margin % Comparison

For the Biotechnology subindustry, Aprinoia Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aprinoia Therapeutics FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aprinoia Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Aprinoia Therapeutics's FCF Margin % falls into.


Aprinoia Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Aprinoia Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-14.916/9.069
=-164.47 %

Aprinoia Therapeutics's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin=Free Cash Flow (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-9.344/0.035
=-26,697.14 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of -26,697.14% mean?
Aprinoia Therapeutics (APRI) has a FCF Margin % of -26,697.14% as of Dec. 2023. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Aprinoia Therapeutics and its competitors.
Is Aprinoia Therapeutics' FCF Margin % too high?
Aprinoia Therapeutics' current FCF Margin % is -26,697.14%.
How does Aprinoia Therapeutics' FCF Margin % compare to ?
Aprinoia Therapeutics' FCF Margin % of -26,697.14% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Aprinoia Therapeutics and its competitors. Aprinoia Therapeutics's current FCF Margin % is -26,697.14%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aprinoia Therapeutics stock overvalued right now?
Aprinoia Therapeutics (APRI) has a current FCF Margin % of -26,697.14%. The current FCF Margin % is -26,697.14%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Aprinoia Therapeutics (APRI), the current FCF Margin % is -26,697.14% as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aprinoia Therapeutics Business Description

Comparable Companies
Address 245 Main Street, 2nd Floor, Cambridge, MA, USA, 02142
Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("?-Syn") that are toxic to brain cells.